Outset Medical (Nasdaq: OM) shares got a boost today on fourth-quarter results that topped the consensus forecast on Wall ...

Q4 2024 Earnings Call Transcript February 19, 2025 Outset Medical, Inc. beats earnings expectations. Reported EPS is $-0.37, ...

Outset provided 2025 revenue guidance of $115 million to $125 million, and non-GAAP gross margin guidance in the high-30% range. Additionally, the company expects to use less than $50 million of cash ...

Outset Medical is prominently recognized for its innovative Tablo Hemodialysis System, which revolutionized the dialysis ...

Outset Medical Inc (OM) reports sequential revenue growth, improved gross margins, and a strengthened balance sheet, despite challenges in console sales and manufacturing overhead.

Outset Medical (Nasdaq: OM) announced today that the FDA says it addressed all issues cited in a 2023 warning letter.

Outset provided 2025 revenue guidance of $115M to $125M , and non-GAAP gross margin guidance in the high-30% range. Additionally, the company ...

Outset Medical, Inc., a medical technology company focused on innovative dialysis solutions, announced that the FDA has confirmed the resolution of all issues raised in a Warning Letter the ...

Outset Medical, Inc. (OM) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

Welcome to the Outset Medical fourth-quarter 2024 earnings conference call. (Operator Instructions) Please be advised today's conference is being recorded. I would now like to hand the conference over ...

SAN JOSE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and ...